Department of Respiratory Medicine, Kamei Internal medicine and Respiratory Clinic, Takamatsu, Japan
ActiGraph's Response to COVID-19 - July 30th Update
Please join us August 20th for a live webinar:
Remote Data Capture Strategies to Move Academic Research Forward During a Global PandemicRegister Now
Clinical benefit of two-times-per-day aclidinium bromide compared with once-a-day tiotropium bromide hydrate in COPD: a multicentre, open-label, randomised study
- Published on July 26, 2019
Chronic obstructive pulmonary disease (COPD) is mainly treated pharmaceutically with bronchodilators. The purpose of this study was to evaluate the clinical benefits of two-times-per-day aclidinium bromide (Acli-BID) compared with once-a-day tiotropium bromide hydrate (Tio-QD) in patients with COPD.
This study was a multicentre, open-label, randomised study.
Fourcentres in Kagawa prefecture, Japan.
Patients who were diagnosed to have COPD Grade 2–3 according to the Global Initiative for Chronic Obstructive Lung Disease 2015 criteria were enrolled.
Patients were randomly assigned to receive Acli-BID or Tio-QD at a 1:1 ratio, and followed for 8 weeks. Acli-BID was administered in the morning and night, and Tio-QD was administered in the night.
Primary and secondary outcome measures
Primary outcome was forced expiratory volume in one second area under the curve (FEV1AUC0-3), and secondary outcomes were pulmonary function, physical activity, St George’s Respiratory Questionnaire (SGRQ), modified Medical Research Council (mMRC), the 8-item Short-Form Health Survey (SF-8) and COPD exacerbations. Adverse events were evaluated during the study.
44 patients were included in this study. FEV1AUC0-3 at week 8 was 4.62±1.43 L·hour in Acli-BID and 4.73±1.60 L·hour in Tio-QD (mean difference (MD) −0.11 L·hour; 95% CI), −1.04 to 0.83). Significant improvement was observed in activity-related subscales of SGRQ (MD −7.78; 95% CI −14.61 to −0.94) and SF-8 (MD 4.01; 95% CI 0.37 to 7.65), mMRC (MD −0.66; 95% CI −1.19 to −0.13) and rate ratio (0.52, 95% CI 0.27 to 0.99) of exacerbations in the Acli-BID compared with the Tio-QD. Acli-BID and Tio-QD significantly improved sedentary behaviour (MD −35.20 min; 95% CI −67.41 to −2.94 and MD −55.40 min; 95% CI −98.15 to −12.77) within each group, but there was no significant difference between the two groups.
Acli-BID as with Tio-QD could be one of the therapeutic options for patients with COPD to improve pulmonary function. Also, our results suggest that intervention with bronchodilators enhanced physical activity in patients with COPD.
- Tadashi Kamei 1
- Hiroyuki Nakamura 2
- Nobuki Nanki 3
- Yoshiaki Minakata 4
- Kazuto Matsunaga 5
- Yoshihiro Mori 6
Department of Pulmonary Medicine, Sakaide City Hospital, Sakaide, Kagawa, Japan
Department of Respiratory Medicine, Sanuki Municipal Hospital, Sanuki, Kagawa, Japan
Department of Respiratory Medicine, National Hospital Organization Wakayama Hospital, Wakayama, Japan
Department of Respiratory Medicine and Infectious Disease, Graduate school of Medicine, Yamaguchi University, Ube, Japan
Sleep and Respiratory Disease Center, KKR Takamatsu Hospital, Takamatsu, Kagawa, Japan